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Abstract
Background
Seizures are the main cause of maternal death in women with epilepsy, but there are no
tools for predicting seizures in pregnancy. We set out to develop and validate a prognostic
model, using information collected during the antenatal booking visit, to predict seizure risk
at any time in pregnancy and until 6 weeks postpartum in women with epilepsy on antiepilep-
tic drugs.
Methods and findings
We used datasets of a prospective cohort study (EMPiRE) of 527 pregnant women with epi-
lepsy on medication recruited from 50 hospitals in the UK (4 November 2011–17 August
2014). The model development cohort comprised 399 women whose antiepileptic drug
doses were adjusted based on clinical features only; the validation cohort comprised 128
women whose drug dose adjustments were informed by serum drug levels. The outcome
was epileptic (non-eclamptic) seizure captured using diary records. We fitted the model
using LASSO (least absolute shrinkage and selection operator) regression, and reported
the performance using C-statistic (scale 0–1, values > 0.5 show discrimination) and calibra-
tion slope (scale 0–1, values near 1 show accuracy) with 95% confidence intervals (CIs).
We determined the net benefit (a weighted sum of true positive and false positive classifica-
tions) of using the model, with various probability thresholds, to aid clinicians in making indi-
vidualised decisions regarding, for example, referral to tertiary care, frequency and intensity
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of monitoring, and changes in antiepileptic medication. Seizures occurred in 183 women
(46%, 183/399) in the model development cohort and in 57 women (45%, 57/128) in the vali-
dation cohort. The model included age at first seizure, baseline seizure classification, history
of mental health disorder or learning difficulty, occurrence of tonic-clonic and non-tonic-
clonic seizures in the 3 months before pregnancy, previous admission to hospital for sei-
zures during pregnancy, and baseline dose of lamotrigine and levetiracetam. The C-statistic
was 0.79 (95% CI 0.75, 0.84). On external validation, the model showed good performance
(C-statistic 0.76, 95% CI 0.66, 0.85; calibration slope 0.93, 95% CI 0.44, 1.41) but with
imprecise estimates. The EMPiRE model showed the highest net proportional benefit for
predicted probability thresholds between 12% and 99%. Limitations of this study include the
varied gestational ages of women at recruitment, retrospective patient recall of seizure his-
tory, potential variations in seizure classification, the small number of events in the validation
cohort, and the clinical utility restricted to decision-making thresholds above 12%. The
model findings may not be generalisable to low- and middle-income countries, or when infor-
mation on all predictors is not available.
Conclusions
The EMPiRE model showed good performance in predicting the risk of seizures in pregnant
women with epilepsy who are prescribed antiepileptic drugs. Integration of the tool within
the antenatal booking visit, deployed as a simple nomogram, can help to optimise care in
women with epilepsy.
Author summary
Why was this study done?
• Pregnant women with epilepsy are at increased risk of death and complications from
seizures; their high-risk status during pregnancy and after childbirth is often not
recognised.
• Knowledge of an individual’s risk of seizures could help healthcare professionals and
pregnant women make decisions regarding management.
• To our knowledge, there are currently no models to predict risk of seizures in pregnant
women with epilepsy on medication.
What did the researchers do and find?
• We developed the EMPiRE model to predict the risk of seizures in pregnancy and up to
6 weeks after delivery in women with epilepsy on medication whose drug doses were
managed based on clinical findings; we validated the model in a separate group of
women whose dose management was based on drug levels in the blood.
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individual participant data.
• The model discriminated well between those with and without seizures, with good
agreement between predicted and observed risks across both low- and high-risk
women.
• The model is clinically useful for decision-making where the threshold of choice for sei-
zure risk is between 12% and 99%.
• The model showed promising transportability to the validation cohort.
What do these findings mean?
• The EMPiRE prediction model can be used by healthcare professionals to identify preg-
nant women at high risk of seizures and to plan early referral for specialist input; deter-
mine the need for close monitoring in pregnancy, labour, and after childbirth; and
assess antiepileptic drug management.
• The performance of the model is unlikely to vary with the antiepileptic drug dose man-
agement strategy.
Introduction
Women with epilepsy are 10 times more likely to die in pregnancy than those without the con-
dition [1]—seizures are a common cause of death [2]. Despite warnings from consecutive
reports of the Confidential Enquiry into Maternal Deaths (UK) on the failings in antenatal,
intrapartum, and postnatal management of women with epilepsy, care of these women
remains fragmented [3,4]. A lack of recognition of the women’s high-risk status by profession-
als in primary and in secondary care has been highlighted consistently as the main factor
behind epilepsy-related maternal deaths [2,3,5]. Furthermore, up to 4 in 10 women discon-
tinue their antiepileptic medication in pregnancy due to concerns about the effects of drugs on
the fetus, thereby increasing their risk of seizures [6,7]. Many maternal deaths in women with
epilepsy could be averted with timely specialist input [5]. Seizures in pregnancy also have a
negative impact on daily living. For example, the loss of driving license following seizures
affects employment, relationships, and quality of life [8–10].
Pregnant women with epilepsy at risk of seizures need a personalised management plan for
antenatal, intrapartum, and postnatal care, which requires multidisciplinary input through
joint obstetric neurology clinics; however, these clinics are not available in all healthcare cen-
tres [11]. Furthermore, women at high risk of seizures need close monitoring in labour, with
adequate pain relief measures such as epidural analgesia, and use of long-acting benzodiaze-
pines such as clobazam [11]. Current guidelines recommend the use of these measures in
high-risk women [11]. But a lack of guidance on what constitutes high-risk pregnancy is one
factor that has contributed to variations in the care of pregnant women with epilepsy [11].
Prediction of seizures based on a woman’s individual characteristics not only provides an
accurate picture of the risks to inform decision-making, but also promotes effective communi-
cation between the multi-specialty teams caring for women with epilepsy. A tool for predicting
seizure risk can empower women to make informed decisions on their antenatal and intrapar-
tum care. Furthermore, awareness of one’s risk status may lower any anxiety arising from the
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unpredictable nature of seizures [12], and promote adherence to medication through risk-
informed counselling [13].
To our knowledge, there are currently no models to predict seizure risk in pregnant women
with epilepsy. Existing, small retrospective studies provide imprecise estimates of the perfor-
mance of individual predictors, such as type of seizures and seizure status in pre-pregnancy
[14–16]. We aimed to develop and externally validate a prognostic model to predict the risk of
seizures in pregnant women with epilepsy on medication, until 6 weeks postpartum. We also
planned to determine the net benefit of using the model at various threshold probabilities
using decision curve analysis.
Methods
We developed and validated the prognostic model for seizures in the prospective multicentre
EMPiRE (AntiEpileptic drug Monitoring in PREgnancy) study, which recruited pregnant
women with epilepsy on antiepileptic drugs at first antenatal visit from 50 maternity units in
the UK between 4 November 2011 and 17 August 2014 [17]. The UK National Research Ethics
Committee approved the EMPiRE study (11/WM/0164), written consent was obtained from
participants, and the protocol can be accessed at https://www.journalslibrary.nihr.ac.uk/
programmes/hta/095538#/. The research reported here did not require further review by an
ethics committee. We reported our prognostic study in line with the TRIPOD (Transparent
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) recom-
mendations, and present our findings as a nomogram, a graphical representation of the model
to calculate an individual’s risk of seizure [18–20] (S1 TRIPOD Checklist).
Model development and validation cohorts
EMPiRE was a prospective study, and recruited pregnant women with epilepsy on lamotrigine,
carbamazepine, phenytoin, or levetiracetam before 24 weeks’ gestation. Serum antiepileptic
drug levels were assessed every month, but the women and clinicians were blinded to these lev-
els. For women for whom drug levels remained stable, the blinding was maintained (non-ran-
domised cohort) until delivery, and drug doses were adjusted based on clinical features, in line
with national recommendations [17,21]. Women whose serum drug levels fell were randomly
allocated either to a strategy of adjusting antiepileptic doses based on serum drug levels (after
unblinding) or to a strategy of changing the drug doses based on only clinical features (blind-
ing maintained). All participants were followed up until 6 weeks after delivery (S1 Appendix).
The study is described in detail elsewhere [17]. For model development, we used the cohort of
women who were managed without routine serum drug level monitoring (non-randomised
and randomised women), which is in line with standard epilepsy care in the UK [17,21]. We
validated the model in the separate cohort of women managed differently, with routine thera-
peutic drug monitoring, as practised in some countries such as the US, to determine if the
model was transportable across varied healthcare practices [22].
Candidate predictors
A multidisciplinary team of neurologists, obstetricians, and researchers selected the candidate
predictors for further evaluation in the prognostic model, based on existing evidence and their
relevance to clinical care [14,16,23–26]. From an initial list of 65 baseline variables, we selected
the following candidate predictors: age at first seizure, history of learning difficulty or mental
health disorder, baseline seizure classification (tonic-clonic, non-tonic-clonic, unspecified),
history of seizure in the 3 months before pregnancy (tonic-clonic, non-tonic-clonic), number
of seizures between start of pregnancy and baseline visit, type of antiepileptic drug taken at
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baseline, dose of antiepileptic drug taken at baseline, gestational age at baseline, and hospital
admission for seizures in a previous pregnancy. All continuous predictors were assumed to be
linearly associated with the outcome.
Outcome
Our main outcome was the occurrence of tonic-clonic (convulsive) or non-tonic-clonic (non-
convulsive) seizure [27]. Participants prospectively recorded their epileptic seizures, if any, in
purpose-built seizure diaries. To avoid overfitting of multivariable models, the rule of thumb is
to ensure that there are 10 events for each predictor variable that was considered for inclusion
in the model [28]; we worked within this rule limitation.
We assessed the predictive performance of the model using measures of discrimination (C-
statistic) and accuracy (calibration slope). The C-statistic represents the ability of the model to
discriminate between those who do and do not experience seizures; a value of 1 indicates per-
fect discrimination, and a value of 0.5 indicates no discrimination beyond chance [29]. Models
are considered to have a good performance when the C-statistic exceeds 0.7 [30]. Calibration
refers to agreement between the predicted and observed risk of seizure for all groups of pre-
dicted probabilities. A well-calibrated model will have a calibration slope of 1, and all groups
will fit close to this line.
Statistical analysis
Model development. Missing values were imputed using 10-fold multiple imputation by
chained equations. Within each imputed dataset we developed a multivariable logistic regres-
sion model using the LASSO (least absolute shrinkage and selection operator) method, which
simultaneously selects the variables and penalises the model coefficients for over-optimism.
We selected the lambda parameter that minimised expected model deviance. Final coefficients
were combined across imputed datasets using Rubin’s rule [31,32]. Confidence intervals for
model coefficients were obtained by bootstrap sampling. Bootstrap validation was carried out
to adjust the performance of the model for optimism. We repeated the entire modelling pro-
cess on 100 bootstrap samples drawn from each of the 10 imputed datasets. We did not con-
sider the number of tonic-clonic seizures between the diagnosis of pregnancy and baseline
visit as a variable, as it was highly correlated with the predictor variable of tonic-clonic seizure
history in the 3 months before pregnancy.
We assessed the overall discriminatory ability of the model using the C-statistic (summa-
rised as the area under receiver operating characteristic curve [AUC ROC]) with 95%
confidence interval (CI). Model calibration was visually assessed with a calibration plot repre-
senting deciles of predicted probability of seizure against the observed rate in each risk group.
The calibration slope was also calculated, which is the slope of the regression line fitted
between predicted and observed risk probabilities on the logit scale, with 1 being the ideal
value.
External validation. We externally validated the final model in a separate cohort of
women whose drug levels were routinely monitored (therapeutic drug monitoring) to plan
drug dose adjustments. We report the predictive performance in this cohort using the same
measures of discrimination and calibration as used in the model development cohort [33].
We visually assessed the model’s calibration by plotting quartiles of predicted probability
of seizure against the observed rate in each quartile, and estimated the calibration slope
[34,35].
Sensitivity analysis. We undertook sensitivity analysis by combining all available data in
the development and validation cohorts to determine if there was any change in model
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performance. We evaluated antiepileptic drug dose monitoring strategy (therapeutic drug
monitoring versus clinical features monitoring) as a predictor while developing the combined
model.
Decision curve analysis. We performed decision curve analysis to assess the clinical value
of the model. A decision rule should take into consideration the identification of women likely
to have seizures because of the significant consequences (maternal death, accidents, loss of
driving license), and the avoidance of unnecessary interventions leading to adverse impact on
mother or baby. We determined the net benefit of the model across a wide range of threshold
probabilities, instead of simply classifying all pregnant women with epilepsy as predicted to
have seizures or classifying no women as predicted to have seizures [36]. We represent the net
benefit as a function of the decision threshold in a decision curve plot.
The choice of thresholds will vary according to the planned intervention, the preference of
the clinician, and the preference of the mother. For example, if the intervention involves refer-
ral of a pregnant woman with epilepsy to a tertiary unit for antenatal and intrapartum care, at
a low threshold, false negatives are minimised at the expense of unnecessary referrals to ter-
tiary care. At a high threshold, fewer women are referred, but women who are likely to benefit
may be denied access to tertiary care. We expect an intermediate range of thresholds to be clin-
ically acceptable. But if the planned intervention is to increase the dose and number of antiepi-
leptic drugs—which can have adverse side effects on the mother and increase the risk of long-
term neurodevelopmental problems in the child—clinicians may choose a higher threshold
than what was chosen for tertiary referral.
Nomogram. We also developed a simple, easy-to-use nomogram to calculate the pre-
dicted probability of seizures in pregnant women at the time of antenatal booking.
The analyses were performed using Stata software version 15.1 and R software version 3.3.2
[37,38].
Results
The EMPiRE study recruited 560 pregnant women. The model development cohort included
399 women; the validation cohort included 128 women (S1 Appendix).
Characteristics of the women
The average gestational age at baseline was 16.6 weeks (SD 4.0) in the development cohort and
14.9 weeks (SD 4.4) in the validation cohort (Table 1). The mean age at first seizure was similar
in both cohorts, at 16 years, and 10%–15% of women had a learning difficulty or mental health
disorder. A similar proportion of women in the development and validation cohorts were pre-
viously diagnosed to have tonic-clonic seizures (development, 39%; validation, 36%). Overall,
46% (182/399) of women in the development cohort and 39% (50/128) in the validation cohort
had experienced seizures in the 3 months prior to pregnancy. Lamotrigine was the commonest
antiepileptic drug prescribed in both cohorts; more than half of the women took lamotrigine
in the development (226/399, 57%) and validation cohorts (80/128, 63%).
Model performance
Overall, 46% (183/399) of women in the development cohort experienced 1 or more seizures
at any time from baseline until 6 weeks after delivery. Tonic-clonic seizures accounted for half
of all seizures (90/183, 49%). Eight predictors were significantly associated with seizures and
were included in the final multivariable model: age at first seizure, history of mental health dis-
order or learning difficulty, baseline seizure classification (tonic-clonic, non-tonic-clonic,
unspecified), hospital admission for seizures in a previous pregnancy, tonic-clonic seizure in
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the 3 months before pregnancy, non-tonic-clonic seizure in the 3 months before pregnancy,
baseline dose of lamotrigine, and baseline dose of levetiracetam (Table 2). The model is pre-
sented as a graphical calculator (nomogram) in Fig 1.
The equation of the EMPiRE prediction model for risk of seizures during pregnancy and
until 6 weeks after delivery in women with epilepsy on antiepileptic drugs was as follows:
probabilityðseizureÞ ¼ expðYÞ=ð1þ expðYÞÞ
where Y = −1.39 + (−0.02 � age at first seizure) + 0.61 [unspecified seizures] + 0.75 [non-tonic-
clonic seizures] + (0.02 � dose of levetiracetam/100) + (0.29 � dose of lamotrigine/100) + 0.66
[non-tonic-clonic seizures in the 3 months before pregnancy] + 1.97 [tonic-clonic seizures in
the 3 months before pregnancy] + 0.67 [learning difficulty or mental health disorder] + 0.17
[admitted to hospital for seizures during previous pregnancy].
Table 1. Details of women’s characteristics in the development and validation cohorts of the EMPiRE prediction model and the proportion with missing data.
Characteristic Development cohort (n = 399) Validation cohort (n = 128)
Mean (SD) or n
(%)
Number with missing data, n
(%)
Mean (SD) or n
(%)
Number with missing data, n
(%)
Gestational age at baseline (weeks) 16.6 (4.0) 0 14.9 (4.4) 0
History of learning difficulty or mental illness 50 (13%) 1 (0.3%) 20 (16%) 0
Age at first seizure (years) 16.5 (7.4) 5 (1.3%) 16.8 (7.8) 0
�10 years 70 (17.8%) 28 (21.9%)
11–20 years 215 (54.6%) 59 (46.1%)
21–30 years 94 (23.9%) 35 (27.3%)
31–40 years 15 (3.8%) 6 (4.7%)
Admission to hospital for seizures in previous
pregnancy
28 (7.0%) 22 (5.5%) 14 (10.9%) 7 (5.5%)
Seizure classification at baseline
Tonic-clonic 155 (39%) 0 46 (36%) 0
Non-tonic-clonic 232 (58%) 0 78 (61%) 0
Unspecified 12 (3%) 0 4 (3%) 0
Seizure in the 3 months before pregnancy 182 (46%) 50 (39%)
Tonic-clonic 52 (13%) 83 (20.8%) 12 (9%) 32 (25.0%)
Non-tonic-clonic 130 (33%) 0 38 (30%) 0
Number of seizures in pregnancy prior to the baseline
visit
Tonic-clonic 0.7 (2.8) 82 (20.6%) 0.4 (2.1) 31 (24.2%)
Non-tonic-clonic 11.6 (108.4) 0 18.1 (83.4) 0
Antiepileptic drug intake at baseline
Carbamazepine 74 (19%) 0 16 (13%) 0
Lamotrigine 200 (50%) 0 66 (52%) 0
Levetiracetam 99 (25%) 0 31 (24%) 0
Phenytoin 0 0 1 (1%) 0
Lamotrigine and carbamazepine 1 (0.3%) 0 — 0
Lamotrigine and levetiracetam 25 (6%) 0 14 (11%) 0
Baseline dose of antiepileptic drugs (mg/day)
Carbamazepine 706.0 (348.5) 0 612.5 (346.2) 0
Lamotrigine 272.1 (155.6) 0 269.4 (160.6) 0
Levetiracetam 1,641.3 (886.8) 0 1,533.3 (760.5) 0
Phenytoin 0 0 200 (—) 0
https://doi.org/10.1371/journal.pmed.1002802.t001
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All variables were coded as binary (1 when present and 0 when absent) except for age at
first seizure (years), dose of lamotrigine (mg/day), and dose of levetiracetam (mg/day).
The apparent C-statistic for the model was 0.80 (95% CI 0.76, 0.85). After bootstrap adjust-
ment for optimism, the final prediction model had a C-statistic of 0.79 (95% CI 0.75, 0.84) to
discriminate between women with and without seizures (Table 3). The optimism-adjusted cal-
ibration plot (Fig 2) showed mostly good agreement between the predicted and observed risks,
and the calibration slope was 1.26 (95% CI 0.98, 1.54).
Our sensitivity analysis, which combined all available data (n = 527), resulted in a model
with the same predictors and similar coefficients as the EMPiRE model developed using only
the development cohort. The antiepileptic drug monitoring strategy was not found to be a sig-
nificant predictor of seizures and was therefore not selected in the combined model. The C-
statistic and calibration slope of the combined model were 0.78 (95% CI 0.74, 0.82) and 1.22
(95% CI 0.44, 1.46), respectively (S2 Appendix).
External validation and predictive performance
In the external validation cohort, 45% (57/128) of women experienced seizures at any time
from baseline until 6 weeks after delivery; tonic-clonic seizures were reported in 39% (22/57)
of women who had seizures. The final model showed good discrimination when externally val-
idated, with a C-statistic of 0.76 (95% CI 0.66, 0.85). The model showed mostly good agree-
ment between the predicted and observed risks, with a calibration slope of 0.93 (95% CI 0.44,
1.41) (Fig 2).
Table 2. Multivariable LASSO logistic regression of seizure risk prediction in pregnant women with epilepsy.
Candidate predictor Multivariable analysis after MI
(n = 399)
OR Bootstrap 95% CI
Age at first seizure (years) 0.98 0.97, 0.99
History of learning difficulty or mental illness 1.96 1.68, 2.89
Seizure classification at baseline (ref. tonic-clonic)
Non-tonic-clonic 2.11 1.88, 2.62
Unspecified 1.85 1.64, 4.30
Tonic-clonic seizure in the 3 months prior to pregnancy 7.20 6.63, 11.93
Non-tonic-clonic seizure in the 3 months prior to pregnancy 1.94 1.71, 2.38
Baseline dose of lamotrigine (×100 mg/day) 1.34 1.30, 1.44
Baseline dose of levetiracetam (×100 mg/day) 1.02 1.01, 1.03
Admitted to hospital for seizures in previous pregnancy 1.19 1.08, 1.92
Baseline dose of carbamazepine (×100 mg/day) — —
Number of non-tonic-clonic seizures since the start of pregnancy — —
Gestational age at baseline (weeks) — —
95% CI: Bootstrap limits of the confidence interval obtained from percentiles 2.5 and 97.5. Missing values were
imputed using 10-fold MI by chained equations (step 1). We fitted a regression model using the LASSO strategy in
each of the 10 imputed datasets (step 2). We averaged model coefficients using Rubin’s rule to get the final model
coefficients (step 3). To obtain non-parametric 95% confidence intervals for model coefficients, we repeated the
previous step 2 and step 3 on 1,000 bootstrap samples. Limits of the 95% confidence interval for each coefficient were
the 2.5th and 97.5th percentiles of their distribution.
MI, multiple imputation; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002802.t002
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Net benefit of model use
In our decision curve analysis (Fig 3), the curve for the EMPiRE model showed positive net
benefit for predicted probability thresholds between 12% and 99% compared to managing
Fig 1. EMPiRE nomogram for predicting the risk of seizures at antenatal booking in pregnant women with epilepsy
on antiepileptic drugs: A worked example.
https://doi.org/10.1371/journal.pmed.1002802.g001
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pregnant women with epilepsy as if they will all have seizures or managing them as if none of
them will have seizures (i.e., treat-all or treat-none strategies). Table 4 provides estimates of
the net benefit of using the model for various probability thresholds. For low thresholds, below
12%, there was no difference between using the EMPiRE model and treating women as if they
will all have seizures.
Discussion
Summary of the findings
The EMPiRE model performs well in predicting the risk of seizures at the time of antenatal
booking in pregnant women with epilepsy who are prescribed antiepileptic medication. The
Table 3. EMPiRE model performance.
Performance measure Development cohort (n = 399) Validation cohort (n = 128)
C-statistic 0.79 (95% CI 0.75, 0.84) 0.76 (95% CI 0.66, 0.85)
Calibration slope 1.26 (95% CI 0.98, 1.54) 0.93 (95% CI 0.44, 1.41)
https://doi.org/10.1371/journal.pmed.1002802.t003
Fig 2. Calibration of the EMPiRE prediction model by comparing observed versus predicted risk of seizures in
pregnant women on antiepileptic drugs, with a frequency histogram. Top panel = development cohort; bottom
panel = validation cohort.
https://doi.org/10.1371/journal.pmed.1002802.g002
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model incorporates routinely available characteristics that are easy to measure, such as age at
first seizure, type of seizures, seizures in the 3 months before pregnancy, mental health, admis-
sion to hospital for seizures during a previous pregnancy, and dose of antiepileptic drugs. The
model is clinically useful over a range of threshold probabilities, and is relevant to general
practitioners, epilepsy specialists, obstetricians, and midwives in identifying high-risk women.
The model shows potential for transportability across risk groups to settings where routine
therapeutic drug monitoring is undertaken, but the findings should be interpreted with cau-
tion due to the small number of events in the validation sample. Our simple nomogram is
designed to facilitate the model’s use in clinical practice.
Strengths and limitations
To our knowledge, ours is the only clinical prognostic model to predict seizures in pregnant
women with epilepsy. We developed the model using data from a prospective, high-quality,
multicentre study. We evaluated predictors that were clinically relevant and routinely available
to healthcare professionals, so that the model can be easily applied in clinical practice. Missing
values of predictors were dealt with by multiple imputation, thereby avoiding loss of useful
information [39,40]. We developed the model to predict seizures not only in pregnancy, but
up to 6 weeks after delivery, a period with increased risks to the mother and baby [11,41]. We
adjusted for optimism and addressed issues around overfitting in the model. In addition to
providing the model as an easy-to-use nomogram, we provided information on its clinical
use at various threshold probabilities for decision-making [35]. The model includes clinical
Fig 3. Decision curve analysis using the EMPiRE seizure risk prediction model. Red line (treat none) = net benefit when we assume that no
pregnant woman with epilepsy will have the outcome (seizure in pregnancy); blue line (treat all) = net benefit when we assume that all pregnant
women with epilepsy will have the outcome; green line (EMPiRE nomogram) = net benefit when we manage pregnant women with epilepsy
according to the predicted risk of the outcome (seizure in pregnancy) estimated by the EMPiRE model. The preferred strategy is the one with
the highest net benefit at any given threshold.
https://doi.org/10.1371/journal.pmed.1002802.g003
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variables that are easily accessible at the time of booking for incorporation into an app or inte-
gration into computer systems within healthcare services. A convenient and easy-to-use
nomogram of the EMPiRE model allows for immediate use of the model to predict the risk of
seizures without the need to remember the formulae behind it.
Our model development and validation approach took into account the significant varia-
tions in the management of antiepileptic drug dosages in pregnancy to prevent seizures [42].
While the American Academy of Neurology recommends routine serum therapeutic drug
monitoring, with dosage increased if the serum drug level falls [22], the UK National Institute
for Health and Care Excellence, Royal College of Obstetricians and Gynaecologists, and Scot-
tish Intercollegiate Guidelines Network guidelines do not recommend routine drug monitor-
ing but drug dose adjustments based mainly on clinical features [11,21,43]. In this paper, we
developed and internally validated the model in women whose drug dose was managed based
on clinical features to determine the accuracy and reproducibility of the model. Through our
external validation, we assessed the transportability of the model to women managed using a
different management strategy (therapeutic drug monitoring), which appears promising [44].
Furthermore, when we developed the combined model by using all available data (including
women routinely and not routinely monitored for drug levels) in our sensitivity analysis, we
did not observe any differences either in the number and type of predictors or in the model’s
performance compared to the model developed using only women in the development cohort.
The antiepileptic drug dose monitoring strategy was not identified to be a significant predictor
in the combined model, implying that the model is generalisable irrespective of the strategy.
There are some limitations to this study. The cohorts consisted of women recruited with
pre-specified criteria, which may limit the use of the model in all women [19,45]. We did not
Table 4. Net benefit of using the EMPiRE prediction model compared to managing women with epilepsy assuming all of them will have seizures in pregnancy or
the postpartum period.
Threshold probability Net benefit Advantage of using the model
Treat all women EMPiRE model Difference in net benefit Reduction in number who do not need the intervention per 100 women
0.05 0.430 0.430 0 0
0.1 0.398 0.398 0 0
0.15 0.363 0.368 0.003 2
0.2 0.323 0.329 0.008 3
0.25 0.278 0.299 0.018 6
0.3 0.227 0.276 0.049 11
0.35 0.167 0.266 0.100 19
0.4 0.098 0.248 0.150 22
0.45 0.016 0.213 0.207 25
0.5 −0.083 0.193 0.286 29
0.55 −0.203 0.166 0.372 30
0.6 −0.353 0.164 0.503 34
0.65 −0.547 0.120 0.663 36
0.7 −0.805 0.111 0.911 39
0.75 −1.165 0.088 1.253 42
0.8 −1.707 0.073 1.774 44
0.85 −2.609 0.057 2.668 47
0.9 −4.414 0.030 4.454 49
0.95 −9.827 0.023 9.852 52
0.99 −53.135 0.000 53.135 54
https://doi.org/10.1371/journal.pmed.1002802.t004
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include women on sodium valproate; this is consistent with current recommendations against
valproate use in pregnancy, due to the increased risk of birth defects and neurodevelopmental
disorders [46]. The model can only be used in women managed on phenytoin, lamotrigine,
levetiracetam, or carbamazepine and when information is available on all predictors in the
context of care in a high-income setting. This limits its transportability to low- and middle-
income countries with resource constraints and non-availability of these drugs [47]. Women
were recruited at varied gestational ages. However, we evaluated gestational age as a predictor,
and it was not selected by the modelling strategy in the final model. The model included his-
tory of seizures in the 3 months before pregnancy obtained through retrospective recall, with
resultant bias. We consider this to reflect the real life scenario, where women who do not
receive pre-pregnancy specialist epilepsy care often do not maintain a prospective seizure
diary prior to seeing an epilepsy specialist in pregnancy. It is possible that a different predictor
such as history of seizures in the 9 months before pregnancy instead of the 3-month history in
our model may have improved its performance [48,49]. We only included clinical predictors
routinely available at the time of antenatal booking, and did not evaluate other tests such as
electroencephalogram (EEG) or MRI, or risk factors such as history of nocturnal or prolonged
seizures, which may be available in specialist epilepsy care. We could not assess any changes
in antiepileptic medication before conception because this information was not routinely
recorded at antenatal booking, and was not collected in the EMPiRE trial. These additional
variables may have improved the performance of the model. Due to the small sample size and
the small number of events in the validation cohort (<100), we were limited in our interpreta-
tion of the transportability of the model [50].
Comparison to existing evidence
To our knowledge, 2 other prediction models exist for seizures, both involving non-pregnant
individuals: seizure prediction in children and adults who have recently stopped their antiepi-
leptic drugs, reported using individual participant data (IPD) meta-analysis, and prediction of
subsequent seizures after a single seizure in individuals without clear indication to commence
treatment (MESS study) [51,52]. Some predictors in the IPD meta-analysis model such as the
age at onset of epilepsy were also present in our model. It is not appropriate or feasible to
apply other variables, such as seizure-free interval before antiepileptic drug withdrawal and
epileptiform abnormality on EEG, to the pregnant population [51]. The performance of our
EMPiRE model was better than that of the IPD meta-analysis model (C-statistic 0.65) [51].
The MESS study, which used split sample validation, did not report the performance of the
model with currently recommended measures such as C-statistic and calibration slope, and
hence we are unable to compare that model with the EMPiRE model.
Other individual studies such as the EURAP (European and International Registry of Anti-
epileptic Drugs and Pregnancy) have reported on the association between maternal risk factors
and seizures in pregnancy—none provided multivariable prognostic models [14,16]. Com-
pared to a third of pregnant women with epilepsy on medication developing seizures in the
EURAP study, 46% of women in the EMPiRE cohorts experienced seizures in pregnancy or
until 6 weeks after delivery [14,23]. This difference could be attributable to the known increase
in seizures that occurs after delivery in new mothers, as EURAP did not include postnatal
mothers or prospective seizure diaries [41]. Inclusion of a selective group of women in the
EMPiRE study may also have contributed to the difference. Similarly to the EURAP study, our
final model identified lamotrigine dose to be a predictor of seizures [14]. Another small retro-
spective study identified pre-pregnancy seizure status to be the main predictor of seizures in
pregnancy [16], which was also the strongest predictor of seizures in our model.
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Relevance to clinical care
Currently pregnant women with epilepsy are managed by varied healthcare professionals such
as general practitioners, obstetricians and midwives, and epilepsy specialists. There is no clear
pathway for multidisciplinary communication. Joint obstetric neurology clinics are not avail-
able in half of the maternity units in UK, a major hindrance for integration of epilepsy care
within antenatal care [53]. The first step towards achieving integrated care is effective risk
communication of the mother’s seizure status. Such a risk-based approach using quantified
risk estimates can help to avoid maternal deaths such as those reported in the MBRRACE-UK
(Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the
UK) report [5], where women with epilepsy were never treated by an epilepsy specialist in
pregnancy, and were left unmonitored during their hospital admissions without specialist
input [5].
We refrained from recommending specific decision thresholds for various interventions as
these are likely to vary with the potential adverse effects and costs of the planned intervention.
For example, primary care clinicians may consider a 20% cutoff, a level of risk associated with
driving restrictions, to be appropriate to make decisions on early referral to tertiary units with
joint obstetric neurology clinics. However, secondary care clinicians may choose a higher
threshold when the intervention involves frequent antenatal monitoring (weekly or fort-
nightly), intrapartum use of invasive interventions for pain relief such as epidural and other
medications (such as clobazam, which carries a risk of neonatal respiratory depression), or
close monitoring in the postnatal period. The choice of threshold in a clinical setting is also
likely to vary depending on the epilepsy syndrome and seizure types. For example, the inter-
vention threshold may be lower for patients who tend to experience convulsive seizures than
for those who experience absence seizures.
Women’s choice of thresholds may depend on the additional time and resources required
(for example, long-distance travel to access tertiary care) and the perceived risks to themselves
and their babies from the various interventions. If the ability to drive is crucial to the mother
for her job and other responsibilities, after discussion with clinicians, she may opt for a lower
threshold for interventions in secondary care. But if minimising the risk of long-term adverse
offspring neurodevelopmental outcomes is valued more by the mother than minimising the
risk of seizures, she may choose a higher threshold for increasing the dose and number of anti-
epileptic drugs. Our decision curve analysis shows that the model is useful across a wide range
of threshold probabilities.
Use of the model in clinical practice should be complementary to individualised advice on
safety, risk assessment, drug adherence, and triggers for seizures. Awareness of seizure risk can
minimise non-adherence to medication in pregnancy, one of the major factors behind seizure
deterioration in pregnancy [6,7,13]. Women predicted to have a low risk of seizure by the
model should be informed that their risk status is subject to adherence to their antiepileptic
medication. The EMPiRE model does not identify women below 12% risk. Women and clini-
cians should be aware of this limitation if the probability threshold to make decisions on eligi-
bility for home or water birth is below this threshold.
Relevance to research
The effect of the addition of other markers, such as EEG findings or historical MRI brain imag-
ing reports, on the performance of the model needs further evaluation. There is a need for
multiple external validations across different settings and populations to fully appreciate the
transportability of the model [54]. The impact of using the EMPiRE model in clinical practice
needs to be evaluated through cluster-randomised trials, to assess whether it helps improve
Predicting seizures in pregnant women with epilepsy
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002802 May 13, 2019 14 / 18
outcomes such as the seizure-free period or quality of life of these women. While the tool is
expected to improve women’s knowledge of their risk status for seizures in pregnancy, the
effect of the EMPiRE model on women’s anxiety levels is not known and needs to be assessed.
Further studies are needed to assess the acceptability of the tool to women with epilepsy and to
healthcare providers, their preferred thresholds of choice, and the cost utilities of consequences
of decisions for various false positive and false negative cases.
Conclusions
The EMPiRE nomogram is a simple 8-item prediction tool to calculate the individualised risk
of seizures at antenatal booking in pregnant women with epilepsy on antiepileptic drugs. The
estimates can help guide individually tailored choices made by patients and clinicians, which
may influence the intensity of monitoring in pregnancy and after delivery, place of care, and
antiepileptic drug dose adjustment strategy. The model is not clinically useful for decision-
making at very low thresholds.
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